Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index; 5 of the 13 sources its claims cite were checked for support.
Abstract
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at a concentration of 0.4 microM. Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and proscillaridin A, which inhibited HIF-1alpha protein synthesis and expression of HIF-1 target genes in cancer cells. Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within one week. Enforced expression of HIF-1alpha by transfection was not inhibited by digoxin, and xenografts derived from these cells were resistant to the anti-tumor effects of digoxin, demonstrating that HIF-1 is a critical target of digoxin for cancer therapy.
Overview
CoChat Summary
TL;DR
A screen of 3,120 clinically used or trial drugs identified cardiac glycosides, including digoxin, as potent inhibitors of HIF-1α protein synthesis. Digoxin blocked HIF-1 target gene expression and inhibited tumor xenograft growth, with resistance in cells expressing HIF-1α from a transfected vector lacking HIF-1α mRNA untranslated regions.
Key findings
- In a Hep3B-c1 reporter screen, 336 of 3,120 drugs reduced hypoxia-induced firefly/Renilla luciferase activity by ≥50% at 10 µM; after re-screening, the top 20 drugs caused ≥88% inhibition at 0.4 µM, and 11 of these 20 were cardiac glycosides, including digoxin, ouabain, and proscillaridin A.
- Cardiac glycosides inhibited hypoxia-induced HIF-1α and HIF-2α protein expression at concentrations ≥50 nM and decreased mRNA levels of HIF-1 target genes HK1, HK2, and GLUT1 at 1% O2, without inhibiting HIF-1α mRNA.
- Digoxin inhibited HIF-1α protein synthesis independently of the PHD-VHL-proteasome pathway, mTOR/RPS6, Na+/K+ ATPase α1, and topoisomerases; pulse-labeling showed digoxin reduced de novo HIF-1α synthesis by 73% while overall protein synthesis was inhibited by only 19%.
- In SCID mouse xenografts, daily i.p. digoxin at 0.5 or 2 mg/kg inhibited P493-Myc tumor growth dose-dependently; 2 mg/kg inhibited PC3 tumor growth, and delayed treatment of established tumors (mean volume 100 mm3) caused growth arrest within 7 days. PC3-CA5 xenografts expressing constitutively active HIF-1α were resistant to digoxin’s anti-tumor effect.
Methods
- Cell-based screen using Hep3B-c1 cells stably transfected with an HRE-driven firefly luciferase reporter and a constitutive Renilla luciferase reporter; the Hopkins Drug Library of 3,120 FDA-approved or phase II drugs was screened at 10 µM, then re-screened at 2 µM and 0.4 µM.
- Mechanistic assays included immunoblotting for HIF-1α/HIF-2α, quantitative real-time RT-PCR for HIF-1 target mRNAs, [35S]methionine/cysteine pulse-labeling with HIF-1α immunoprecipitation, shRNA knockdown of Na+/K+ ATPase α1 and topoisomerases, flow cytometry, and annexin V staining.
- In vivo studies used SCID mice bearing P493-Myc, PC3-EV, or PC3-CA5 xenografts; digoxin was administered by daily intraperitoneal injection, with tumor volume, body weight, tumor HIF-1α protein, and HIF-1 target gene mRNAs assessed.
Limitations
- The paper states that digoxin has both HIF-1α-dependent and HIF-1α-independent effects on cell growth, based on PC3-CA5 cells growing similarly to vehicle-treated PC3-EV cells.
- Evident from the text: the mechanistic and in vivo work relies on specific cell lines and SCID mouse xenograft models, with no human clinical outcomes reported.
- The provided text is truncated before the end of the Discussion, so any additional limitations stated there are not available.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 4 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIF-1 also controls the expression of genes involved in tumor cell immor- talization, stem cell maintenance/de-differentiation, genetic in- stability, autocrine growth, invasion/metastasis, and treatment failure (6, 7).”
What the sources say
- Not checked — no full text of the sourcecites [6] matched to “Evaluation of HIF-1 inhibitors as anticancer agents” (2007) source
- Partly supportedcites [7] matched to “The role of hypoxia-inducible factors in tumorigenesis” (2008) sourceExperimental — accuracy not yet measured
The Figure 3 caption (Angiogenesis section; page not provided) says HIF-regulated genes contribute to proliferation, invasion, and metastasis, and the Differentiation discussion links HIF signaling to an undifferentiated state. But the review does not establish that HIF-1 controls genes for every listed outcome: it attributes direct Oct4 regulation to HIF-2, does not substantiate immortalization or genetic instability, and describes HIF-1’s effects on radiotherapy response as mixed rather than simply causing treatment failure. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Digitoxin inhibited the development of skin pap- illomas in mice treated with dimethylbenzanthracene and tetra- decanoylphorbol ester (34).”
What the sources say
- Supportedcites [34] matched to “Anti-tumor Promoting Activities of Natural Products. II. Inhibitory Effects of Digitoxin on Two-Stage Carcinogenesis of Mouse Skin Tumors and Mouse Pulmonary Tumors.” (1993) source
The Results and Discussion (p. 1) report that digitoxin delayed skin papilloma formation and reduced both the proportion of mice bearing papillomas and the average number per mouse. The figure caption on the same page identifies DMBA as the initiator and TPA as the promoter. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of digoxin-treated PC3-CA5 cells was similar to that of vehicle-treated PC3-EV cells.”
§ 4 h pretreatment > 1.00 0.31 0.270.12
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When Hep3B-c1 cells were cultured under hypoxic conditions (1% O2), the ratio of firefly/Renilla luciferase activity was ten-fold higher than when the cells were cultured under nonhy- poxic conditions (20% O2) for 24 h (Fig. 1B).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were obtained in Hep3B cells treated with 100 nM digoxin (Fig. 1G).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 27 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, pharmacologic depletion of HIF1α by small molecules PX478 and Digoxin41,42 also produced similar results in T and NK cells (Fig. 4g, h and Fig. S5f, g, h).”
From Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy (2022) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Digoxin, which is currently passing phase I clinical trials, was reported to inhibit established tumor xenografts with no effect on the growth of constitutively expressing HIF-1 xenografts.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vivo, digoxin inhibits tumor growth and suppresses lung metastasis in orthotopic breast cancer models [295,297].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In HepB cells, these agents reduced both HIF-1α and HIF-2α protein levels without altering HIF1A mRNA, indicating post-transcriptional regulation [295].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [295]
Experimental — accuracy not yet measuredIn the citing paper
“One significant hurdle for the use of these compounds, however, is the lack of specificity of these compounds for specific blockade of HIF (such as digoxin, acriflavine, and 17-AAG) identified to date [124–126].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [125]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“HIF-1 is a heterodimeric protein that is composed of O2regulated HIF-1 and constitutively expressed HIF-1 subunits (8, 9).”
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“VHL loss-of-function results in constitutive expression of HIF-1 in the majority of clear cell renal carcinomas (11).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“Under normoxic conditions, HIF-1 is hydroxylated on proline residue 564 and/or 402 by proline hydroxylase domain protein 2 (PHD2), which is required for the binding of the von Hippel-Lindau protein (VHL), the recognition subunit of an E3 ubiquitin-protein ligase that targets HIF-1 for proteasomal degradation (10).”
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
(1999) · PubMed · Cited by 2,204
Self-citationPurification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Self-citationRas, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“Whereas VHL loss-of-function leading to dysregulated HIF-1 expression is restricted to renal cell carcinoma and cerebellar hemangioblastoma, many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., & Giallongo, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32529 · Cited by 1,752
Self-citationTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Cited by
Items 401–500 of 620
Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer
Ajith, T. A. (2018) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2017-0167 · Cited by 21
Wei, J., Yang, Y., Li, Y., Mo, X., Guo, X., Zhang, X., Xu, X., Jiang, Z., & You, Q. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.021 · Cited by 22
Intra-arterial and Oral Digoxin Therapy for Retinoblastoma
Patel, M. M., Paulus, Y. M., Gobin, Y. P., Djaballah, H., Marr, B. P., Dunkel, I. J., Brodie, S. E., Antczak, C., Folberg, R., & Abramson, D. H. (2011) · Ophthalmic Genetics · doi:10.3109/13816810.2010.544530 · Cited by 20
Wissing, M. D., Mendonca, J., Kim, E., Kim, E., Shim, J. S., Kaelber, N. S., Kant, H., Hammers, H. J., Commes, T., van Diest, P. J., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23759 · Cited by 17
“This type of screen has gained prominence due to its success in identifying cytotoxic agents that target cells with mutations in a particular gene.(19,20) The JHDL used in our study has previously been used to identify new antitumor agents, such as mycophenolic acid, nitroxoline, itraconazole and ketoconazole as poten…”
BackgroundMethodSelf-citationHippo in Gastric Cancer: From Signalling to Therapy
Seeneevassen, L., Dubus, P. R., Gronnier, C., & Varon, C. (2022) · Cancers · doi:10.3390/cancers14092282 · Cited by 18
Alevizopoulos, K., DIMAS, K. S., Papadopoulou, N., Schmidt, E.-M., Tsapara, A., Alkahtani, S. H., Honisch, S., Prousis, K. C., Alarifi, S. A., Calogeropoulou, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8329 · Cited by 17
Zhou, X., Chen, M., Zheng, Z., Zhu, G., Jiang, Z., & Bai, L. (2017) · RSC Advances · doi:10.1039/c7ra02238g · Cited by 18
Li, G., Lu, W., Wu, X., Cheng, J., Ai, R., Zhou, Z.-H., & Tang, Z. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0073-6 · Cited by 20
“Second, previous studies have shown that digitalis can inhibit the synthesis of HIF-1α [41].”
BackgroundRed ginseng deregulates hypoxia-induced genes by dissociating the HIF-1 dimer
Choi, Y.-J., Choi, H., Cho, C., & Park, J. (2011) · Journal of Natural Medicines · doi:10.1007/s11418-010-0504-8 · Cited by 17
“Briefly, their modes of HIF-1 inhibition are: inhibition of HIF-1a synthesis [25], destabilization of HIF1a [26], blockade of p300/CBP recruitment by HIF-1a [27], and inhibition of DNA binding of HIF-1 [28].”
BackgroundWang, X., Gao, X., Liu, H., et al. (2010) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-010-0033-z · Cited by 17
Self-citationLi, S., Hsu, C.-W., Sakamuru, S., Zou, C., Huang, R., & Xia, M. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317729792 · Cited by 17
ASC modulates HIF-1α stability and induces cell mobility in OSCC
Wu, C., Chang, I. Y., Hung, J.-L., Liao, W., Lai, Y.-R., Chang, K., Li, H., & Chang, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02927-7 · Cited by 19
Zhu, S., Abudupataer, M., Yan, S., Wang, C., Wang, L., & Zhu, K. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114747 · Cited by 16
Atrial fibrillation and breast cancer—Vicious twins? A systematic review and meta-analysis
Yao, X., Hu, Q., Liu, X., Ling, Q., Leng, Y., Zhao, H., Yu, P. C., Ma, J., Zhao, Y., Liu, M., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1113231 · Cited by 15
“Recent studies have shown that cardiac glycosides exert antitumor effects through different mechanisms (57, 58).”
BackgroundNew uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
Jamshed, F., Dashti, F., Ouyang, X., Mehal, W. Z., & Banini, B. A. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1824 · Cited by 17
Kaapu, K. J., Murtola, T. J., Talala, K. M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.328 · Cited by 16
“Digoxin has been proposed to inhibit HIF-1a protein synthesis and the expression of HIF-1a target genes in prostate tumours (Zhang et al, 2008).”
BackgroundTherapeutic Strategies to Block the Hypoxic Response
DiGiacomo, J. W., & Gilkes, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_10 · Cited by 17
Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1
Muthamil, S., Kim, H. Y., Jang, H., Lyu, J., Shin, U. C., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114802 · Cited by 17
Davis, D. A., Shrestha, P., & Yarchoan, R. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29071 · Cited by 15
Lima, E. D. O., Guerreiro, T. M., Melo, C. F. O. R., de Oliveira, D. N., Machado, D., Lancelloti, M., & Catharino, R. R. (2017) · Journal of Mass Spectrometry · doi:10.1002/jms.4058 · Cited by 18
“That means that digoxin might function as an mRNA translational regulator at UTRs from HIF-1α mRNA generated [43, 44].”
BackgroundDrzyzga, A., Cichoń, T., Czapla, J., Jarosz–Biej, M., Pilny, E., Matuszczak, S., Wojcieszek, P., Urbaś, Z., & Smolarczyk, R. (2021) · Cancers · doi:10.3390/cancers13163924 · Cited by 15
“An example of such an inhibitor is digoxin, which reduces the amount of HIF-1α transcription factor and inhibits the growth of tumors in mice [58].”
BackgroundZhao, S., Li, X., Wu, W., et al. (2021) · Andrologia · doi:10.1111/and.14217 · Cited by 15
Effects of medications on hypoxia‐inducible factor in the retina: A review
Kim, A. H., Kolesnikova, M., Ngo, W. K., & Tsang, S. H. (2023) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14161 · Cited by 14
Agamia, N., Sorror, O. A., Sayed, N. M. E., Ghazala, R. A., Echy, S. M., Moussa, D. H., & Melnik, B. C. (2023) · Archives of Dermatological Research · doi:10.1007/s00403-023-02594-6 · Cited by 14
Anticancer Properties of Cardiac Glycosides
Pongrakhananon, V. (2013) · InTech eBooks · doi:10.5772/55381 · Cited by 20
“…I and II and an increase in the intracellular Ca 2+ concentration [41] Induction of cell cycle arrest through the upregulation of HIF-1α [42] Ouabain Depletion of Na + /K + -ATPase and upregulation of p21 [39] Increase in the intracellular Ca 2+ concentration [40] Inhibition of DNA…”
Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.
Park, S., & Chan, C. (2012) · PubMed · doi:10.14670/hh-27.975 · Cited by 15
“In addition, drugs like topotecan and digoxin can effectively block HIF synthesis at low concentrations (Melillo, 2007; Zhang et al., 2008).”
Meng, Q., Qin, Y., Deshpande, M. M., Kashiwabuchi, F., Rodrigues, M. W., Lu, Q., Ren, H., Elisseeff, J. H., Semenza, G. L., Montaner, S., et al. (2017) · PubMed Central · doi:10.1167/iovs.17-21974 · Cited by 14
Self-citationWeng, J.-R., Bai, L., Chiu, S.-J., Chiu, C., Lin, W.-Y., Hu, J., & Shieh, T. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.004 · Cited by 15
Gobbi, S., Belluti, F., Rampa, A., & Bisi, A. (2021) · Molecules · doi:10.3390/molecules26144228 · Cited by 15
“Thus, the potential synergistic effect that could be obtained with the combination of DMXAA and digoxin, a known inhibitor of HIF-1α expression [41], was recently considered [42].”
BackgroundCouraud, S., Dell’Aniello, S., Bouganim, N., & Azoulay, L. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3058-8 · Cited by 13
Digitalis use and risk of gastrointestinal cancers: A nationwide population-based cohort study
Xie, S.-H., Jernberg, T., Mattsson, F., & Lagergren, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16151 · Cited by 16
Interdependence of hypoxia and β-adrenergic receptor signaling in pulmonary arterial hypertension
Stephens, O. R., Weiss, K., Frimel, M., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00015.2019 · Cited by 14
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
Self-citationBayona, C., Alza, L., Ranđelović, T., Sallan, M. C., Visa, A., Cantí, C., Ochoa, I., Oliván, S., & Herreros, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06492-1 · Cited by 19
Sharma, S., Mazumder, A. G., Rana, A. K., Patial, V., & Singh, D. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190801112027 · Cited by 13
Xiao, Y., Yan, W., Guo, L., Meng, C., Li, B., Neves, H., Chen, P.-C., Li, L., Huang, Y., Kwok, H. F., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6096 · Cited by 13
Introduction of Adonis aestivalis as a new source of effective cytotoxic cardiac glycoside
Hosseini, M., Taherkhani, M., & Nohooji, M. G. (2017) · Natural Product Research · doi:10.1080/14786419.2017.1413573 · Cited by 13
“Oleandrin, digitoxin and ouabain have been reported to induce apoptosis in androgen independent PC cells, although the specific mechanism of drug action has not yet been identified (Raghavendra et al. 2007; Fretz et al. 2008; Lefranc and Kiss 2008; Zhang et al. 2008).”
BackgroundWeng, L., Zhao, M., Chen, Z., & Zhu, L. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01325 · Cited by 12
Otto, C., Kastner, C., Schmidt, S., Uttinger, K., Baluapuri, A., Denk, S., Rosenfeldt, M. T., Rosenwald, A., Roehrig, F., Ade, C. P., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13265 · Cited by 14
Hypoxia makes EZH2 inhibitor not easy—advances of crosstalk between HIF and EZH2
Huang, Z., Tang, Y., Zhang, J., Huang, J., Cheng, R., Guo, Y., Kleer, C. G., Wang, Y., & Xue, L. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae017 · Cited by 14
Jiang, W., Li, X., Li, T., Wang, H., Shi, W. Q., Qi, P., Li, C., Chen, J., Bao, J., Huang, G., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3860 · Cited by 11
“In silico drug repositioning by screening existing approved drugs for previously unknown indications is therapeutically essential and efficient for drug discovery (8-10).”
Rafei, A. E., Trachtenberg, B. H., Schultz, J., John, R., Estep, J. D., Araujo‐Gutierrez, R., Suarez, T. E. E., Goodwin, K., & Cogswell, R. J. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.03.005 · Cited by 12
Yokoyama, S., Sugimoto, Y., NAKAGAWA, C., Hosomi, K., & Takada, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-53392-y · Cited by 12
Crezee, T., Tesselaar, M. H., Nagarajah, J., Corver, W. E., Morreau, J., Pritchard, C. A., Kimura, S., Kuiper, J. G., Grunsven, I. V. E., Smit, J. W. A., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00588-y · Cited by 13
Advances in Cancer Stem Cell Biology
Scatena, R., Giardina, B., & Mordente, A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0809-3 · Cited by 14
Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments
Yadav, D. K., Yadav, R. K., Singh, A., Huang, Y., Bao, D., Yang, Z., Huang, H., Jiang, Y., Wang, P., Lin, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1704868 · Cited by 15
“Digoxin suppresses HIF-1 a translation, inhibiting tumor growth and MDSC recruitment by disrupting HIF-1/LOX-mediated premetastatic niche formation (624, 625).”
Jin, Y. H., Peng, Y., Xu, J., Yuan, Y., Yang, N., Zhang, Z., Xu, L., Li, L., Xiong, Y., Sun, D., et al. (2024) · Oncogenesis · doi:10.1038/s41389-024-00508-3 · Cited by 13
Lindholm, H., Ejeskär, K., & Szekeres, F. L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158237 · Cited by 15
“Digitoxin is a well-known cardiac glycoside [9–11] with the potential to act as a potent anti-cancer drug in the therapeutic concentration range of 25–40 nM [10,12,13].”
BackgroundHIF-1α inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics
Lin, J., & Carducci, M. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802683081 · Cited by 10
Formation of New High Density Glycogen-Microtubule Structures Is Induced by Cardiac Steroids
Fridman, E., Lichtstein, D., & Rosen, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.273698 · Cited by 11
“level, in addition to inhibiting the activity of the Na ,K ATPase, CS-Na ,K -ATPase interactions were shown to induce the activation of several signal transduction pathways (15, 26), suppression of cell differentiation by antagonizing RORyt activity (32), inhibition of interferon- gene expression (33), regulation of t…”
BackgroundAssociations between systemic medications and development of wet age‐related macular degeneration
Loukovaara, S., Auvinen, A. P., & Haukka, J. K. (2021) · Acta Ophthalmologica · doi:10.1111/aos.15056 · Cited by 13
“It inhibits hypoxiainducible factor (HIF)-1 transcriptional activity (Zhang et al. 2008).”
BackgroundWeidemann, H. (2012) · Journal of Carcinogenesis · doi:10.4103/1477-3163.92999 · Cited by 10
“[35-46] These include, for example induction of apoptosis via Ca2+-dependant caspase-3 activation,[47] promotion of cell cycle arrest and cell differentiation via upregulation of the cell cycle inhibitor p21cip1,[48] cell growth inhibition via downregulation of the NKA-α1 isoform,[49] NF-кB,[50] HIF-1α[51] as well as…”
BackgroundZhou, S., Song, X., Zeng, W., & Chen, D. (2025) · Pharmaceuticals · doi:10.3390/ph18101521 · Cited by 17
“These agents suppress cancer cell proliferation, migration, and invasion, and can also induce tumor cell lysis [85,86,237,287].”
Pandey, S., Singh, R., Habib, N., Tripathi, R., Kushwaha, R., & Mahdi, A. A. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.4.1121 · Cited by 13
“…can be inhibited by various metabolites-based drugs, including aminoflavone [68], GL331 [69], and anthracyclines [70], cardiac glycosides [71], steroids [72], topoisomerase inhibitors [73], and microtubule-binding agents [74] inhibitor of histone deacetylase, [75], MPT0G157, another…”
Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy
de Keijzer, M. J., de Klerk, D. J., de Haan, L. R., van Kooten, R. T., Franchi, L. P., Dias, L. M., Kleijn, T. G., van Doorn, D. J., Heger, M., & on behalf of the Photodynamic Therapy Study Group (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2099-1_19 · Cited by 14
Lanigan, S. M., & O'Connor, J. J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.11.011 · Cited by 12
Repurposing existing agents as adjunct therapies for glioblastoma
Purow, B. W. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv041 · Cited by 10
Digoxin lowers the incidence of prostate cancer: A nationwide population-based study
Lin, T., Fan, Y.-H., Chen, Y., & Huang, W. J. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000288 · Cited by 10
Ha, D. P., Shin, W.-J., Liu, Z., Doche, M. E., Lau, R., Leli, N. M., Conn, C. S., Russo, M., Lorenzato, A., Koumenis, C., et al. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01297-3 · Cited by 12
“For instance, digoxin has been reported to suppress the expression of HIF-1α, which is an important protein for both cancer and SARS-CoV-2 infection [36, 39, 40].”
Ainembabazi, D., Geng, X., Gavande, N. S., Turchi, J. J., & Zhang, Y. (2022) · ChemMedChem · doi:10.1002/cmdc.202200415 · Cited by 9
Vincent, F., Nguyen, M. T. L., Emerling, D. E., Kelly, M. G., & Duncton, M. A. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.086 · Cited by 10
Koivunen, P., Fell, S. M., Lu, W., Rabinowitz, J. D., Kung, A. L., & Schlisio, S. (2016) · Hypoxia · doi:10.2147/hp.s96366 · Cited by 10
“42 More recently, BAY87-2243, an inhibitor of hypoxia-inducible gene activation demonstrated antitumoral activity under Glc deprivation and reduced the growth of H460 tumor xenografts.”
Wang, G., Wang, J., Yin, P., Xu, K., Wang, Y., Shi, F., Gao, J., & Fu, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27388 · Cited by 9
“In the extracellular space, all of these bioactive lipids can be found among the secreted body (Zhang et al., 2008); therefore, as a potential cancer treatment in the future, potential cancer treatments can be considered to reduce the generation of exogenous and secretion, or modifying the exosome…”
BackgroundJoe, N. S., Wang, Y., Oza, H. H., Godet, I., Milki, N., Riggins, G. J., & Gilkes, D. M. (2023) · Cancers · doi:10.3390/cancers15041330 · Cited by 9
“Interestingly, well-known HIF inhibitors [26] had connectivity scores within the same range as tubulin inhibitors, the most well-accepted mechanism of action for MBZ (Figure 1a,b).”
BackgroundMethodHypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas
Ponnaluri, V. K. C., Vavilala, D. T., Prakash, S., & Mukherji, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.028 · Cited by 10
Cell signaling and cancer‐possible targets for therapy
Wenner, C. E. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22021 · Cited by 9
HIF-α factors as potential therapeutic targets in leukemia
Magliulo, D., & Bernardi, R. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1538357 · Cited by 12
“Digoxin was first found to arrest tumor growth in xenograft models of different tumors [79], and several pharmacodynamics and phase I/II clinical trials are currently ongoing where digoxin is administered either alone or in combination with other agents for the treatment of breast cancer, sarcoma and head and neck can…”
BackgroundSpleen Tyrosine Kinase Contributes to Müller Glial Expression of Proangiogenic Cytokines in Diabetes
Yerlikaya, E. I., Toro, A. L., Sunilkumar, S., VanCleave, A. M., Leung, M., Kawasawa, Y. I., Kimball, S. R., & Dennis, M. D. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.11.25 · Cited by 9
Li, W., Chen, Y.-C., Lin, Y., Zou, Y.-Q., Hu, G.-S., Yang, J.-J., Nie, X. Y., Li, M.-Y., Wang, Y., He, Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115487 · Cited by 13
Self-citationRole of Digoxin in Preventing Cigarette Smoke-Induced COPD via HIF-1α Inhibition in a Mouse Model
Zhang, K., Zhou, F., Zhu, C., Yuan, L., Li, D., Wang, J., & Lu, W. (2025) · International Journal of COPD · doi:10.2147/copd.s493856 · Cited by 9
Drug Repositioning Strategies to Explore New Candidates Treating Prostate Cancer
Turanlı, B., & Arğa, K. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00027-4 · Cited by 9
Pleiotropic Effects of Dronedarone on Ischemia/Reperfusion Injury in Heart and Brain
Heusch, G., & Schulz, R. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6379-z · Cited by 8
“High digoxin concentrations also inhibit HIF-1 synthesis [70, 71], which otherwise might have contributed to dronedarone’s neuroprotection (see above).”
BackgroundMan, S., Wang, H., Zhou, J., et al. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00318 · Cited by 8
Wang, F., Liu, L., Tong, Y., Li, L., Liu, Y., & Gao, W. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1716484 · Cited by 9
“shows that Pro A and Digoxin reduce tumor growth by inhibiting HIF-1α synthesis [7].”
BackgroundAbbasi, M. A., Stoller, D. A., LYDEN, E. R., et al. (2022) · The International Journal of Artificial Organs · doi:10.1177/03913988221112684 · Cited by 8
Chan, C.-H., Wu, C.-Y., Dubey, N. K., Wei, H.-J., Lu, J.-H., Mao, S., Liang, J. N., Liang, Y.-H., Cheng, H.-C., & Deng, W. (2020) · Aging · doi:10.18632/aging.103471 · Cited by 11
“Digoxin (Sigma-Aldrich, D6003) was used as an inhibitor of hypoxia-inducible factor 1-alpha [45].”
MethodThe Na + /K + ATPase Regulates Glycolysis and Modifies Immune Metabolism in TumorsPreprint
Sanderson, S. M., Xiao, Z., Wisdom, A. J., Bose, S., Liberti, M. V., Reid, M. A., Hocke, E., Gregory, S. G., Kirsch, D. G., & Locasale, J. W. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.31.018739 · Cited by 10
Isaacs, J. T., Dalrymple, S. L., Antony, L., Rosen, D. M., Coleman, I. M., Nelson, P. S., Kostova, M. B., Murray, I. A., Perdew, G. H., Denmeade, S. R., et al. (2023) · The Prostate · doi:10.1002/pros.24606 · Cited by 8
“We and others have documented that compounds that decrease HIF‐1α protein are therapeutic in vivo against a variety of preclinical solid malignancy models, including prostate cancer.(13,15,54,61,62) The present studies document that TasQ reversibly binds with a 1 μM EC50 to HDAC4 producing a negative allosteric effect…”
BackgroundContrasting effects of cardiac glycosides on cisplatin- and etoposide-induced cell death
Kulikov, A. V., Slobodkina, E. A., Alekseev, A., Gogvadze, V. G., & Zhivotovsky, B. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0101 · Cited by 7
Spontaneous Transformation of Lamellar Structures from Simple to More Complex States
Dou, Y., Long, P., Dong, S., et al. (2013) · Langmuir · doi:10.1021/la402993y · Cited by 7
Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis
Zhang, C., Xie, S.-H., Xu, B.-F., et al. (2017) · Drug Safety · doi:10.1007/s40264-016-0484-z · Cited by 7
Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A
Lee, J. Y., Kim, M., Lee, M. S., Ju, J. E., Chung, N., & Jeong, Y. K. (2017) · Bioscience Reports · doi:10.1042/bsr20171257 · Cited by 7
Cedilanid inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy.
Zhang, J. S., Wang, J. D., An, Y., Xiong, Y., Li, J., Jonas, J., Xu, L., Zhang, W., & Wan, X. H. (2017) · PubMed Central · Cited by 8
Ouabain – a double-edged sword in tumor development and progression? a review of half a century
Weidemann, H., Sarsour, A. D., & Brodie, C. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1685871 · Cited by 7
“They showed that Digoxin administration increased latency and decreased growth of tumor xenografts, whereas treatment of established tumors resulted in growth arrest within 1 week (Zhang et al., 2008).”
InfluentialAlshahrani, A., Alsubait, A., Asiri, Z. A., Alghamdi, S. S., Saqyah, S. B., Alqahtani, T., Fitaihi, R. A., Altuwaijri, N., & Jamous, Y. F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1684896 · Cited by 12
Bokhari, S. M. Z., Aloss, K., Viana, P. H. L., Schvarcz, C. A., Besztercei, B., Giunashvili, N., Bócsi, D., Koós, Z., Balogh, A., Benyó, Z., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00296 · Cited by 9
Positive Inotropic Agents in Cancer Therapy: Exploring Potential Anti-Tumor Effects
Ribeiro, E., & Vale, N. (2024) · Targets · doi:10.3390/targets2020009 · Cited by 7
“Digoxin, traditionally used for heart failure, enhances the effects of radiation therapy in hypoxic tumor environments by inhibiting HIF-1 α [31,32].”
BackgroundLittlefield, A. J., Jones, G., Ciolek, A., yuzefpolskaya, M., & Jennings, D. L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10019-z · Cited by 6
“Digoxin, a cardiac glycoside, is a potent inhibitor of HIF synthesis which may [54] decrease production of Ang-2 and subsequently decrease incidence of GIB (Fig.”
BackgroundDigoxin Attenuates Receptor Activation of NF-κB Ligand-Induced Osteoclastogenesis in Macrophages
Igari, K., Kelly, M. J., & Yamanouchi, D. (2019) · Journal of Vascular Research · doi:10.1159/000499380 · Cited by 7
[Primary progressive aphasia (Mesulam syndrome)].
Habib, M., Pelletier, J., & Khalil, R. (1993) · PubMed · Cited by 6
The unexpected role of Na+ in mitochondrial bioenergetics, ROS production and homeostasis
Hernansanz‐Agustín, P. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110544 · Cited by 8
HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition
Geng, H., Ko, H., Pittsenbarger, J., Harvey, C. T., Xue, C., Liu, Q., Wiens, S., Kachhap, S. K., Beer, T. M., & Qian, D. Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.724059 · Cited by 6
“Further, we treated cancer cells with a sub-toxic dose of a pharmacological HIF inhibitor-digoxin (Zhang et al., 2008).”
MethodInfluentialSelf-citationJensen, C. C., & Warfel, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00039-6 · Cited by 5
Vinod, M., Berthier, A., Maréchal, X., Gheeraert, C., Boutry, R., Delhaye, S., Annicotte, J., Duez, H., Hovasse, A., Cianférani, S., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00148-z · Cited by 5
Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy
Rapisarda, A., & Melillo, G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_1 · Cited by 6
Therapeutic Potential of Cardiac Glycosides Against Cancer
Siti-Syarifah, M. M., & Yunos, N. M. (2018) · Springer eBooks · doi:10.1007/978-981-10-8064-7_4 · Cited by 7
Ascorbate and Tumor Cell Iron Metabolism: The Evolving Story and Its Link to Pathology
Bae, D.-H., Azad, M. G., Kalinowski, D. S., Lane, D. J. R., Jansson, P. J., & Richardson, D. R. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7903 · Cited by 8
Digoxin Induces Human Astrocyte Reaction In Vitro
Pamies, D., Vujić, T., Schvartz, D., Boccard, J., Repond, C., Nunes, C., Rudaz, S. L., Sanchez, J., González‐Ruiz, V., & Zurich, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03057-1 · Cited by 7
Current Drugs and their Therapeutic Targets for Hypoxia-inducible Factors in Cancer
Joshi, E., Pandya, M. D., & Desai, U. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230601092245 · Cited by 5
Hypoxia Inducible Factor-1α in Pulmonary Fibrosis: A Promising Therapeutic Target
Hanumegowda, C., & Mohan, M. E. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.2.2256 · Cited by 7
“In vivo and in vitro studies have demonstrated that digoxin effectively reduces HIF-1 α activity in PC3 cells [38].”
Metadata
- Authors
- Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L.
- Affiliations
- Johns Hopkins University (US)
- Department of Oncology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-12-16
- Volume
- 105
- Issue
- 50
- Pages
- 19579-19586
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2604945
- OpenAlex
- W2135664375
- Semantic Scholar
- ad3fa6ccad907da0a52a0b821d2be70006a9b6fd
- Cited by
- 624
- References
- 40
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 35 · 2021: 39 · 2020: 38 · 2019: 34 · 2018: 34 · 2017: 50 · 2016: 42 · 2015: 37 · 2014: 52 · 2013: 57 · 2012: 38
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Flight Attendant Medical Research Institute
- Johns Hopkins University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- digoxin, cardiac glycosides, HIF-1α, HIF-1, tumor growth inhibition, drug screening, ouabain, proscillaridin A, tumor xenografts, cancer therapy
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Antineoplastic Agents, Cardiac Glycosides, Digoxin, Humans, Transcription, Genetic, Transfection, Protein Biosynthesis, Mice, SCID, Genes, Reporter, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Luciferases, Firefly, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.